These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 3950454)

  • 1. Safety and immunogenicity of a 45-microgram supplemental dose of inactivated split-virus influenza B vaccine in the elderly.
    Arden NH; Patriarca PA; Lui KJ; Harmon MW; Brandon F; Kendal AP
    J Infect Dis; 1986 Apr; 153(4):805-6. PubMed ID: 3950454
    [No Abstract]   [Full Text] [Related]  

  • 2. Antibody response of an elderly population to a supplemental dose of influenza B vaccine.
    Peters NL; Meiklejohn G; Jahnigen DW
    J Am Geriatr Soc; 1988 Jul; 36(7):593-9. PubMed ID: 3385111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of cold-adapted, reassortant influenza B virus vaccines in elderly and chronically ill adults.
    Treanor J; Dumyati G; O'Brien D; Riley MA; Riley G; Erb S; Betts R
    J Infect Dis; 1994 Feb; 169(2):402-7. PubMed ID: 8106775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65 y of age and older.
    Greenberg DP; Robertson CA; Talbot HK; Decker MD
    Hum Vaccin Immunother; 2017 Sep; 13(9):2058-2064. PubMed ID: 28700265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer.
    Carr S; Allison KJ; Van De Velde LA; Zhang K; English EY; Iverson A; Daw NC; Howard SC; Navid F; Rodriguez-Galindo C; Yang J; Adderson EE; McCullers JA; Flynn PM
    J Infect Dis; 2011 Nov; 204(10):1475-82. PubMed ID: 21949042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine (NBP607-QIV): A randomized, double-blind, multi-center, phase III clinical trial in adults and elderly subjects.
    Choi WS; Noh JY; Song JY; Cheong HJ; Wie SH; Lee JS; Lee J; Kim SW; Jeong HW; Jung SI; Kim YS; Woo HJ; Kim KH; Kim H; Kim WJ
    Hum Vaccin Immunother; 2017 Jul; 13(7):1653-1660. PubMed ID: 28406746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A TritonX-100-split virion influenza vaccine is safe and fulfills the committee for proprietary medicinal products (CPMP) recommendations for the European Community for Immunogenicity, in Children, Adults and the Elderly.
    Lina B; Fletcher MA; Valette M; Saliou P; Aymard M
    Biologicals; 2000 Jun; 28(2):95-103. PubMed ID: 10885616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the infectivity, immunogenicity, and efficacy of live cold-adapted influenza B/Ann Arbor/1/86 reassortant virus vaccine in adult volunteers.
    Clements ML; Snyder MH; Sears SD; Maassab HF; Murphy BR
    J Infect Dis; 1990 May; 161(5):869-77. PubMed ID: 2324538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, immunogenicity and cross-reactivity of a Northern hemisphere 2013-2014 seasonal trivalent inactivated split influenza virus vaccine, Anflu®.
    Shen Y; Hu Y; Meng F; Du W; Li W; Song Y; Ji X; Huo L; Fu Z; Yin W
    Hum Vaccin Immunother; 2016 May; 12(5):1229-34. PubMed ID: 26934750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of live attenuated cold-adapted influenza B/Ann Arbor/1/86 reassortant virus vaccine in infants and children.
    Edwards KM; King JC; Steinhoff MC; Thompson J; Clements ML; Wright PF; Murphy BR
    J Infect Dis; 1991 Apr; 163(4):740-5. PubMed ID: 2010627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of a quadrivalent inactivated influenza virus vaccine compared with a comparator quadrivalent inactivated influenza vaccine in a pediatric population: A phase 3, randomized noninferiority study.
    Airey J; Albano FR; Sawlwin DC; Jones AG; Formica N; Matassa V; Leong J
    Vaccine; 2017 May; 35(20):2745-2752. PubMed ID: 28390934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A comparative study of live and inactivated influenza vaccines: the organization of the observation and the results of a study of their reactogenicity and immunogenicity].
    Slepushkin AN; Rudenko LG; Kendal AP; Monto AS; Beliaev AL; Burtseva EI; Grigor'eva EP; Obrosova-Serova NP; Ivanova VT; Bragina VE
    Vopr Virusol; 1994; 39(3):129-31. PubMed ID: 8091754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of the novel seasonal preservative- and adjuvant-free influenza vaccine: Blind, randomized, and placebo-controlled trial.
    Sarsenbayeva G; Volgin Y; Kassenov M; Issagulov T; Bogdanov N; Sansyzbay A; Abitay R; Nurpeisova A; Sagymbay A; Koshemetov Z; Stukova M; Buzitskaya Z; Кulmagambetov I; Karabayeva D; Davlyatshin T; Khairullin B
    J Med Virol; 2018 Jan; 90(1):41-49. PubMed ID: 28842994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunologic reactions following influenza virus vaccination].
    Süss J; Schmidt S; Groh A; Vogt KH; Schmidt J
    Z Gesamte Hyg; 1985 Mar; 31(3):149-53. PubMed ID: 4013413
    [No Abstract]   [Full Text] [Related]  

  • 15. [An immunogenicity and reactogenicity study of a purified, inactivated trivalent influenza vaccine for parenteral administration prepared for the 1996-1997 season].
    Lupulescu E; Ioniţă E; Botez D; Matepciuc M; Tabra ME; Tecu C; Alexandrescu V; Munţiu A
    Bacteriol Virusol Parazitol Epidemiol; 1997; 42(1-2):110-2. PubMed ID: 9235136
    [No Abstract]   [Full Text] [Related]  

  • 16. A prospective, randomized, open-label trial comparing the safety and efficacy of trivalent live attenuated and inactivated influenza vaccines in adults 60 years of age and older.
    Forrest BD; Steele AD; Hiemstra L; Rappaport R; Ambrose CS; Gruber WC
    Vaccine; 2011 May; 29(20):3633-9. PubMed ID: 21440036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity.
    Reisinger KS; Block SL; Izu A; Groth N; Holmes SJ
    J Infect Dis; 2009 Sep; 200(6):849-57. PubMed ID: 19673652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 2013/2014 northern hemisphere season surface antigen inactivated trivalent influenza vaccine--Assessing the immunogenicity and safety in an open label, uncontrolled study.
    Roggelin L; Vinnemeier CD; Meyer S; Witte K; Marx L; Theeß W; Burchard GD; Rolling T; Cramer JP
    Hum Vaccin Immunother; 2015; 11(10):2370-5. PubMed ID: 26114800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of a cell culture-derived inactivated trivalent influenza vaccine (NBP607): A randomized, double-blind, multi-center, phase 3 clinical trial.
    Song JY; Cheong HJ; Lee J; Woo HJ; Wie SH; Lee JS; Kim SW; Noh JY; Choi WS; Kim H; Kim KH; Kim WJ
    Vaccine; 2015 Oct; 33(41):5437-5444. PubMed ID: 26314625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of a paediatric presentation of an influenza vaccine.
    Gonzalez M; Pirez MC; Ward E; Dibarboure H; García A; Picolet H
    Arch Dis Child; 2000 Dec; 83(6):488-91. PubMed ID: 11087282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.